In Stock Cell Lines
Homo sapiens (Human)
Bone
Adherent
The FGFR3 Knockout SW1353 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from a human grade II chondrosarcoma (SW1353). It enables loss-of-function studies of FGFR3, a receptor tyrosine kinase that negatively regulates chondrocyte proliferation and differentiation via MAPK/ERK and PI3K/AKT signaling. Key downstream effectors include CDKN1A (p21) and STAT1. This model is ideal for investigating FGFR3 signaling in cartilage tumors, screening FGFR3 inhibitors, and studying FGF-mediated chondrocyte biology. It also facilitates comparative analysis with FGFR3 gain-of-function mutants in skeletal dysplasias.
Immortalized Human Amniotic Epithelial Cell
Cat. No. ARI0278
NSFL1C Knockout jurkat Polyclonal Cells
Cat. No. ARG13675
ARID4A Knockout jurkat Polyclonal Cells
Cat. No. ARG33908
IL1R1 Knockout HGC-27 Polyclonal Cells
Cat. No. ARG36140
CRLF3 Knockout Raji Polyclonal Cells
Cat. No. ARG1054
Mouse Adipose Vascular Stromal Cells
Cat. No. ARP0581
The FGFR3 Knockout SW1353 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human SW1353 chondrosarcoma model. This loss-of-function system enables precise investigation of FGFR3-mediated signaling in a chondrogenic tumor background, providing a defined genetic tool for pathway dissection.
The SW1353 parental line originates from a grade II chondrosarcoma and carries the IDH2 p.R172S mutation, a hallmark of many cartilaginous tumors. These cells endogenously express FGFR3 and represent a physiologically appropriate model for studying chondrocyte biology and FGFR3-dependent functions in a sarcoma context.
FGFR3 is a receptor tyrosine kinase activated by FGF ligands, including FGF1, FGF2, and FGF18, with heparan sulfate proteoglycans serving as cofactors. Upon ligand binding, receptor dimerization and transphosphorylation recruit the adaptor FRS2, which engages GRB2 and SOS to activate the RAS-RAF-MEK-ERK cascade. Parallel signaling through PI3K stimulates AKT and mTOR, while PLC??1 mediates PKC and calcium mobilization. In chondrocytes, these pathways converge on downstream targets such as the cell cycle inhibitors CDKN1A (p21) and CDKN1B (p27), transcription factors SOX9 and c-FOS, and STAT1, collectively limiting proliferation and promoting differentiation. Interacting proteins like SHP2, SHC1, and CRKL modulate signal strength and specificity.
Knockout of FGFR3 in the SW1353 background abolishes receptor-driven activation of MAPK/ERK and PI3K/AKT pathways, disrupting FGF-mediated growth restraint. This model is particularly informative for interrogating crosstalk between oncogenic IDH2 signaling and FGFR3 cascades, and for assessing how loss of receptor function alters chondrosarcoma cell proliferation, differentiation, and survival. Moreover, because FGFR3 gain-of-function mutations cause achondroplasia and other skeletal dysplasias, this knockout line offers a valuable comparative system for understanding cartilage pathology resulting from receptor loss versus hyperactivation.
The FGFR3 Knockout SW1353 Cell Line is suitable for a wide range of experimental applications, including phospho-ERK and phospho-AKT signaling analysis, Western blot and RT-qPCR validation, MTS or BrdU proliferation assays, Annexin V apoptosis detection, and Alcian blue-based chondrogenic differentiation studies. It serves as an effective platform for screening FGFR3-targeted inhibitors, evaluating FGF ligand responses, and exploring therapeutic vulnerabilities in chondrosarcoma. Researchers may also employ it to study skeletal dysplasia mechanisms or to investigate IDH2-mutant tumor biology. For further technical information or to discuss collaborative applications using this cell line, please contact Ascent Research.
